Ignite Creation Date:
2024-07-17 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06472388
Status:
RECRUITING
Last Update Posted:
2024-06-25
First Post:
2024-05-03
Brief Title:
Everolimus 5 mg vs 10 mgDaily for Patients With Neuroendocrine Tumors
Sponsor:
AC Camargo Cancer Center
Organization:
AC Camargo Cancer Center
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Neuroendocrine Tumors |
| Progression |
| Neuroendocrine Tumor Grade 1 |
| Neuroendocrine Tumor Grade 2 |
| Neuroendocrine Tumor of Pancreas |
| Neuroendocrine Tumor of the Lung |
| Neuroendocrine Tumor Carcinoid |
Keywords: